<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFBF2A7E-9CB1-4B05-A7C8-88903332FF09"><gtr:id>AFBF2A7E-9CB1-4B05-A7C8-88903332FF09</gtr:id><gtr:name>Cochin Institute</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFBF2A7E-9CB1-4B05-A7C8-88903332FF09"><gtr:id>AFBF2A7E-9CB1-4B05-A7C8-88903332FF09</gtr:id><gtr:name>Cochin Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/A97A8EC9-C79E-4701-BC21-6F259E0C8AE9"><gtr:id>A97A8EC9-C79E-4701-BC21-6F259E0C8AE9</gtr:id><gtr:name>Oslo University Hospital</gtr:name><gtr:address><gtr:line1>Ullevaal</gtr:line1><gtr:region>Outside UK</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8B2F9983-D44D-4F52-AB7C-0F3E6FFA64F2"><gtr:id>8B2F9983-D44D-4F52-AB7C-0F3E6FFA64F2</gtr:id><gtr:firstName>Kim</gtr:firstName><gtr:surname>Midwood</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0700108"><gtr:id>2133579B-9E48-46C7-A07A-E526BCD37F63</gtr:id><gtr:title>Regulation of inflammation by endogenous danger signals</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0700108</gtr:grantReference><gtr:abstractText>Rheumatoid arthritis (RA) is an inflammatory disorder that causes the immune system to attack the joints. It is a disabling and painful condition that leads to loss of mobility due to joint destruction. The incidence of RA is 30 cases per 10,000 people; there are more than 350,000 sufferers in the UK alone. RA is a progressive disease, after 5 years ~33% of patients are unable to work, and it shortens life expectancy by 5-10 years.

Inflammation is the first response of the immune system to infection and injury.
It is activated by infectious agents and by molecules made by the body upon injury, known as ?danger signals?. Cells flood the affected area and release cytokines including TNF?, IL-6 and IL-8. Cytokines fight infection and promote repair by removing infectious agents, and degrading dead/damaged tissue. Normally, cytokine activity is tightly controlled; after infection or injury is resolved they are no longer made. 

Autoimmune diseases such as RA result from chronic or ongoing inflammation. What triggers the immune response in RA is unknown but the joint becomes inflamed. Here, cytokines cause degradation of healthy joint tissue. This injury stimulates continued inflammation and a vicious cycle is created that leads to extensive destruction of the joint. 

Current treatments of RA stop joint destruction by inhibiting TNF? and IL-6 action. However, repeated treatments are required, making it expensive, and this approach doesn?t lead to permanent remission. Suppressing the immune response at this level also renders the patient unable to fight infection. Thus, a major goal of our studies is to develop new therapies for RA. 

One group of molecules, called damage associated molecular patterns or DAMPs, are made by the body in response to tissue injury. Levels usually return to normal when repair is complete, however, large amounts are continually produced in autoimmune diseases including RA. We have shown that specific DAMPs stimulate TNF?, IL-6 -8 synthesis in isolated cells. We hypothesize that their persistence in RA drives excessive cytokine production. 

This project aims to determine if inhibition of specific DAMPs in human RA joint tissue prevents cytokine production and whether mice that don?t express these DAMPs are protected from experimentally induced RA. These experiments reveal if blockade of DAMP action will be of clinical benefit. To design strategies that prevent DAMP action we will investigate how these molecules interact with cells to cause cytokine production. Thus we hope to limit excessive tissue damage in RA without compromising patient response to infection.</gtr:abstractText><gtr:technicalSummary>Tenascin-C is an extracellular matrix protein that is specifically and transiently induced upon tissue injury; levels return to normal after repair is complete. Persistent expression of tenascin-C occurs in chronic non-healing wounds and in autoimmune diseases including rheumatoid arthritis (RA). We have shown that tenascin-C induces the synthesis of pro-inflammatory cytokines in primary human macrophages and RA synovial fibroblasts. However, the precise role of tenascin-C in vivo is not known. This study aims to (1) determine if persistent expression of tenascin-C contributes to the pathological progression of RA and (2) to identify the mechanism by which tenascin-C interacts with and signals to cells to mediate an inflammatory response.</gtr:technicalSummary><gtr:fund><gtr:end>2011-07-27</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2008-01-28</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>312377</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Kennedy Institute of Rheumatology</gtr:department><gtr:description>Transcriptional regulation of endogenous danger signals</gtr:description><gtr:id>BFA070AF-3490-4C29-8E99-E2FE13D34960</gtr:id><gtr:impact>This project has generated new data that has been recently published and a grant proposal arising from the data that is currently under review.</gtr:impact><gtr:outcomeId>CC9A85EF6D1-1</gtr:outcomeId><gtr:partnerContribution>The use of newly generated reagents and novel techniques with which to study how the expression of tenasinc-C is regulated</gtr:partnerContribution><gtr:piContribution>generation of new data, access to materials and intellectual input</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Viral exacerbations of asthma and the matrix</gtr:description><gtr:id>D06B5067-9B04-4343-B2CB-5654A3518B17</gtr:id><gtr:impact>Successful PhD studentship application from Asthma UK, student commenced Oct 2015</gtr:impact><gtr:outcomeId>56d04f81ec9975.70550176-1</gtr:outcomeId><gtr:partnerContribution>in vivo and ex vivo models of airway epithelial cell response to rhinoviral infection and asthma</gtr:partnerContribution><gtr:piContribution>Analysis of tenascin-C immune function</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Oslo University Hospital</gtr:collaboratingOrganisation><gtr:country>Norway, Kingdom of</gtr:country><gtr:department>Department of Pathology</gtr:department><gtr:description>IL33 promoter analysis</gtr:description><gtr:id>5D2B9DF0-B80F-4D4B-8861-A8B5FE631047</gtr:id><gtr:impact>19) Sundlis&amp;aelig;ter, E., Edelmann, R. J., Hol, J., Sponheim, J., K&amp;uuml;chler, A. M., Weiss, M., Udalova, I.A., Midwood, K. S., Kasprzycka, M., Haraldsen, G. (2012) The Alarmin Interleukin-33 is a Notch Target in Quiescent Endothelial Cells. American Journal of Pathology 181(3):1099-111.</gtr:impact><gtr:outcomeId>tjyktMvYauj-1</gtr:outcomeId><gtr:partnerContribution>Discovered transcriptional regulation of IL-33 gene during inflammation.</gtr:partnerContribution><gtr:piContribution>Analysis of the promoter region of the Il-33 gene</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>The Roslin Institute</gtr:department><gtr:description>Assays for diagnosing inflammatory diseases</gtr:description><gtr:id>8F59D63E-4832-4E23-976E-4ABD0743096C</gtr:id><gtr:impact>Successful studentship application from MRS, student started Oct 2015</gtr:impact><gtr:outcomeId>56d04ff3a77e28.49197654-1</gtr:outcomeId><gtr:partnerContribution>Murine models of inflammation</gtr:partnerContribution><gtr:piContribution>Analysis of tenascin-C biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cochin Institute (Institut Cochin)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>INSERM U1016</gtr:department><gtr:description>Tumor immunology</gtr:description><gtr:id>C77AF52A-7CC2-4980-AE5E-118ED8832BDA</gtr:id><gtr:impact>Successful grant application, post doc recruited and project commenced Feb 2016</gtr:impact><gtr:outcomeId>56d04ed2da2aa2.15991093-1</gtr:outcomeId><gtr:partnerContribution>In vivo models of tumor progression</gtr:partnerContribution><gtr:piContribution>Analysis of tumor cell activation</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Imperial News</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>61BFCCD8-24B4-40DD-B731-4F291C421CFB</gtr:id><gtr:impact>I was interviewed by Imperial press about the impact of our work on finding new treatments for arthritis for an article in the College newsletter.

The article was published on line and covered by a numer of news sites world wide:


Coverage:


 


United Press International


http://www.upi.com/Science_News/2009/07/02/Rheumatoid-arthritis-signal-molecule-found/UPI-51611246563098/


 


Science Business


http://bulletin.sciencebusiness.net/ebulletins/showissue.php3?page=/548/art/14312


 


Science Daily


http://www.sciencedaily.com/releases/2009/06/090628171953.htm


 


Medical News Today


http://www.medicalnewstoday.com/articles/156219.php


 


Newspost Online


http://www.newspostonline.com/health/scientists-uncover-new-trigger-for-chronic-inflammation-in-rheumatoid-arthritis-2009070262088


 


Innovations Report


http://www.innovations-report.com/html/reports/medicine_health/trigger_chronic_inflammation_rheumatoid_arthritis_135038.html


 


Asia News International (no link)</gtr:impact><gtr:outcomeId>304AEEB2B2A</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>SET for Britain</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>504C4CB1-C18C-48A4-818E-0D9D005E45AD</gtr:id><gtr:impact>Local MP contacted to inform about our work, ~45 politicians attended talk in parliament, sparking discussion afterwards

n/a</gtr:impact><gtr:outcomeId>G3dcBivhLJe</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Policymakers/politicians</gtr:primaryAudience><gtr:year>2010</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>On line interview</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>33BDE878-5183-45CE-8E03-60422C0E2748</gtr:id><gtr:impact>Online interview for undergraduate students discussing the data from our NM paper on new option for treating RA.

Many e mails from students and sufferers of RA asking for more information</gtr:impact><gtr:outcomeId>C2TkajWekFC</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nature Sci Cafe</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>820AE79F-8AC8-4CB3-8F06-A10297647C48</gtr:id><gtr:impact>I was chosen as one of 3 speakers from Europe by the Nature Editoral Board to present to 50 representatives from pharmaceutical companies and venture capitalists, followed by a reception and dinner.

Potential new collaborations in pharma and drug discovery.</gtr:impact><gtr:outcomeId>D2058D90A65</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Industry/Business</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4500</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Royal College of Surgeons small grant</gtr:description><gtr:end>2010-01-02</gtr:end><gtr:fundingOrg>Royal College of Surgeons of England</gtr:fundingOrg><gtr:id>E44527CC-8172-4810-B1A7-07DEFFDA5A57</gtr:id><gtr:outcomeId>56d0550ed861f3.64222928</gtr:outcomeId><gtr:sector>Learned Society</gtr:sector><gtr:start>2009-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>25000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Healing Foundation (Charity for people with disfigurement and visible loss of function)</gtr:department><gtr:description>Healing Foundation project</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>University of Manchester</gtr:fundingOrg><gtr:id>9CC9C10F-9339-4D64-BA7E-EF007887D1A2</gtr:id><gtr:outcomeId>56d05584146195.88432175</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>15000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Imperial Innovations seed funding</gtr:description><gtr:end>2010-09-02</gtr:end><gtr:fundingOrg>Imperial Innovations</gtr:fundingOrg><gtr:id>A2F1F8E1-6374-40B5-87A6-D987AC1E7C04</gtr:id><gtr:outcomeId>56d0554f41e4c5.87998445</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2009-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>222620</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Respivert</gtr:description><gtr:end>2013-08-02</gtr:end><gtr:fundingOrg>Johnson &amp; Johnson</gtr:fundingOrg><gtr:id>1C0F2C4C-B372-4E99-9CA0-6737BFE49644</gtr:id><gtr:outcomeId>56d05627a083a5.64971279</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>AICR project grant</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>World Cancer Research Fund</gtr:fundingOrg><gtr:id>266EC90A-89B8-471E-AF61-6DE77938BC51</gtr:id><gtr:outcomeId>56d05128ce0b69.28624072</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>98000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Asthma UK PhD Studentship</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Asthma UK</gtr:fundingOrg><gtr:id>74AD4582-0D84-42A8-B940-374350C6A2F2</gtr:id><gtr:outcomeId>56d050b8ae2922.13884096</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>59410</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Novimmune project</gtr:description><gtr:end>2011-07-02</gtr:end><gtr:fundingOrg>Novimmune, Geneva</gtr:fundingOrg><gtr:id>379C4D8A-C4B2-434C-8E33-A10FCD19DB42</gtr:id><gtr:outcomeId>56d055b64cdf97.95363471</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120526</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Indigix project</gtr:description><gtr:end>2012-04-02</gtr:end><gtr:fundingOrg>Indigix ltd</gtr:fundingOrg><gtr:id>35A88A27-AF5F-4518-AC6E-DC33E70C90D4</gtr:id><gtr:outcomeId>56d055f4828f33.41531519</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2011-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>205467</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRS studentship</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Scotland</gtr:fundingOrg><gtr:id>BE424923-E5D4-4624-B444-8D2F01BBC649</gtr:id><gtr:outcomeId>56d051650d3353.12187602</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>475000</gtr:amountPounds><gtr:country>Unknown</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Nascient Research Collaboration</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Nascient ltd</gtr:fundingOrg><gtr:id>2DE7EEDE-B61A-46F0-B008-4BBDC24E68B5</gtr:id><gtr:outcomeId>56d051b99fbb52.81307759</gtr:outcomeId><gtr:sector>Private</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BSMB travel bursary</gtr:description><gtr:end>2010-03-02</gtr:end><gtr:fundingOrg>British Society for Matrix Biology (BSMB)</gtr:fundingOrg><gtr:id>099073CE-715F-4DCF-BA9B-3E164F1EDF85</gtr:id><gtr:outcomeId>Wp9tpow3iVu0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ICI travel bursary/International Comgress of Immunology</gtr:description><gtr:end>2009-02-02</gtr:end><gtr:fundingOrg>International Congress of Immunology (ICI)</gtr:fundingOrg><gtr:id>1AF74E69-363F-4CF9-B92E-E20382146D32</gtr:id><gtr:outcomeId>mq1JdtWhrhG0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2009-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>807821</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Arthritis Research UK Senior Fellowship</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Arthritis Research UK</gtr:fundingOrg><gtr:id>847B184C-0804-4903-9223-D4F5787821C6</gtr:id><gtr:outcomeId>WSBfJxAPLJ3</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs><gtr:intellectualPropertyOutput><gtr:description>Tenasicn-C drive Th17 cell polarization in RA</gtr:description><gtr:grantRef>G0700108</gtr:grantRef><gtr:id>B6E351ED-839E-4F45-8ABC-A188AD14C1E4</gtr:id><gtr:impact>Allowed to lapse</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56d728dc535d48.93435737</gtr:outcomeId><gtr:patentId>US 61/718,898</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Biological Materials and Uses Thereof</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Endogenous control of immunity against infection: tenascin-C regulates TLR4-mediated inflammation via microRNA-155.</gtr:description><gtr:grantRef>G0700108</gtr:grantRef><gtr:id>559680BE-747C-4BD8-A208-78C8D344A41B</gtr:id><gtr:impact>Patent discontinued and case closed.</gtr:impact><gtr:licensed>No</gtr:licensed><gtr:outcomeId>56d72bceb06a76.48988342</gtr:outcomeId><gtr:patentId>PCT/GB2013/052276</gtr:patentId><gtr:protection>Patent application published</gtr:protection><gtr:title>Tenascin-C regulates TLR4-mediated immunity via microRNA-155</gtr:title><gtr:yearProtectionGranted>2012</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput><gtr:intellectualPropertyOutput><gtr:description>Activation of FBG domain of tenascin-C of TLR4 drives persistent inflammation in models of RA</gtr:description><gtr:grantRef>G0700108</gtr:grantRef><gtr:id>F48735D2-0168-4C62-BEBB-E931524455A4</gtr:id><gtr:impact>n/a</gtr:impact><gtr:licensed>Yes</gtr:licensed><gtr:outcomeId>56d7281b879309.47160777</gtr:outcomeId><gtr:patentId>P45612EP-EPO</gtr:patentId><gtr:protection>Patent granted</gtr:protection><gtr:title>BIOLOGICAL MATERIALS AND USES THEREOF</gtr:title><gtr:yearProtectionGranted>2013</gtr:yearProtectionGranted></gtr:intellectualPropertyOutput></gtr:intellectualPropertyOutputs><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>LPS free recombinant proteins comprising each region of the large matrix molecule tenacsin-C</gtr:description><gtr:id>95957077-68E6-4C2D-8F3A-D5DFE9A631CD</gtr:id><gtr:impact>Enabled dissection of pro-inflammatory mechanism of action of tenascin-C</gtr:impact><gtr:outcomeId>tgPTMgiMD8K</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>recombinant TNC domains</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2009</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Nascient</gtr:companyName><gtr:description>Nascient is a spin out company whose sole platform is to develop antibodies that block the pro-inflammatory activity of tenascin-C.</gtr:description><gtr:id>5059A72A-6B97-4B75-9865-71800B62A4EF</gtr:id><gtr:impact>n/a</gtr:impact><gtr:outcomeId>n8JCBi3Nb3D</gtr:outcomeId><gtr:yearCompanyFormed>2012</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>9F776EAA-AED6-4756-AAE4-1C85BB756F64</gtr:id><gtr:title>Advances in tenascin-C biology.</gtr:title><gtr:parentPublicationTitle>Cellular and molecular life sciences : CMLS</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7644082a26db28a6a7ae7d2ad5ed88a2"><gtr:id>7644082a26db28a6a7ae7d2ad5ed88a2</gtr:id><gtr:otherNames>Midwood KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1420-682X</gtr:issn><gtr:outcomeId>pm_14219_29_21818551</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C317CC76-8154-4DC0-9D62-BA29606BA337</gtr:id><gtr:title>Identification of novel and distinct binding sites within tenascin-C for soluble and fibrillar fibronectin.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1753d21eb1715bba9efeb3b291ffc760"><gtr:id>1753d21eb1715bba9efeb3b291ffc760</gtr:id><gtr:otherNames>To WS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_14219_29_21324901</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DBE5F61C-BECD-45F6-8413-BB64B3F2153A</gtr:id><gtr:title>Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease.</gtr:title><gtr:parentPublicationTitle>Nature medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a35ea88de80190cc989c086576123d2a"><gtr:id>a35ea88de80190cc989c086576123d2a</gtr:id><gtr:otherNames>Midwood K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1078-8956</gtr:issn><gtr:outcomeId>2B74BC9D076</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>044D11B9-5497-4916-918F-20821A925126</gtr:id><gtr:title>Expression and immune function of tenascin-C.</gtr:title><gtr:parentPublicationTitle>Critical reviews in immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/aaabbeece292eb133ecbd4c49585026d"><gtr:id>aaabbeece292eb133ecbd4c49585026d</gtr:id><gtr:otherNames>Udalova IA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1040-8401</gtr:issn><gtr:outcomeId>pm_14219_29_21542790</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D2ADF45-E32D-498A-A5EE-88F89C68124A</gtr:id><gtr:title>Plasma and cellular fibronectin: distinct and independent functions during tissue repair.</gtr:title><gtr:parentPublicationTitle>Fibrogenesis &amp; tissue repair</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1753d21eb1715bba9efeb3b291ffc760"><gtr:id>1753d21eb1715bba9efeb3b291ffc760</gtr:id><gtr:otherNames>To WS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1755-1536</gtr:issn><gtr:outcomeId>pm_14219_29_21923916</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>10F51E27-7E62-470B-A8E9-25966FD443A7</gtr:id><gtr:title>Toll-like receptor signaling: common pathways that drive cardiovascular disease and rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Arthritis care &amp; research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c1657e2386528e48d6d71c2d57e0d97b"><gtr:id>c1657e2386528e48d6d71c2d57e0d97b</gtr:id><gtr:otherNames>Monaco C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>2151-464X</gtr:issn><gtr:outcomeId>pm_14219_29_21452263</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4E0A6A2E-F6D1-4D3B-855B-927B7FD71B26</gtr:id><gtr:title>The role of tenascin-C in tissue injury and tumorigenesis.</gtr:title><gtr:parentPublicationTitle>Journal of cell communication and signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7644082a26db28a6a7ae7d2ad5ed88a2"><gtr:id>7644082a26db28a6a7ae7d2ad5ed88a2</gtr:id><gtr:otherNames>Midwood KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1873-9601</gtr:issn><gtr:outcomeId>pm_14219_19_19838819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7222DB32-2423-41C7-95AE-682611ADADB6</gtr:id><gtr:title>MicroRNA epigenetics: a new avenue for wound healing research.</gtr:title><gtr:parentPublicationTitle>BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7604e48e538884d0877053d7b79ebefa"><gtr:id>7604e48e538884d0877053d7b79ebefa</gtr:id><gtr:otherNames>Bavan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1173-8804</gtr:issn><gtr:outcomeId>pm_14219_29_21222494</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5B35392-79CA-44F4-A338-749EC9EA427A</gtr:id><gtr:title>Distinct microenvironmental cues stimulate divergent TLR4-mediated signaling pathways in macrophages.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98c1aca47b26397996ca3e73e352d69f"><gtr:id>98c1aca47b26397996ca3e73e352d69f</gtr:id><gtr:otherNames>Piccinini AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn><gtr:outcomeId>58bd9dd91b67d9.69922871</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE63CCE9-DC47-497F-8A36-54C2DBA1AE7C</gtr:id><gtr:title>Endogenous control of immunity against infection: tenascin-C regulates TLR4-mediated inflammation via microRNA-155.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98c1aca47b26397996ca3e73e352d69f"><gtr:id>98c1aca47b26397996ca3e73e352d69f</gtr:id><gtr:otherNames>Piccinini AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>pm_14219_29_23084751</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0B2AF2D0-8228-47E0-837A-1802069469CF</gtr:id><gtr:title>Illustrating the interplay between the extracellular matrix and microRNAs.</gtr:title><gtr:parentPublicationTitle>International journal of experimental pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98c1aca47b26397996ca3e73e352d69f"><gtr:id>98c1aca47b26397996ca3e73e352d69f</gtr:id><gtr:otherNames>Piccinini AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0959-9673</gtr:issn><gtr:outcomeId>56cb4f974ff6b2.44079789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>753F9CEC-1A53-4C2B-A287-DA2D0A99358D</gtr:id><gtr:title>Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis.</gtr:title><gtr:parentPublicationTitle>Rheumatology (Oxford, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/905e16968f95c6747894aa49589fff43"><gtr:id>905e16968f95c6747894aa49589fff43</gtr:id><gtr:otherNames>Goh FG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1462-0324</gtr:issn><gtr:outcomeId>pm_14219_29_21984766</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F5B7935-E779-4B14-A215-EB4672431035</gtr:id><gtr:title>Endogenous activation of adaptive immunity: tenascin-C drives interleukin-17 synthesis in murine arthritic joint disease.</gtr:title><gtr:parentPublicationTitle>Arthritis and rheumatism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/405735481dae7ee7f297152b5e892533"><gtr:id>405735481dae7ee7f297152b5e892533</gtr:id><gtr:otherNames>Ruhmann M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0004-3591</gtr:issn><gtr:outcomeId>pm_14219_29_22275298</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E7E2820E-3808-4CD0-BB55-0B20CA33838B</gtr:id><gtr:title>DAMPening inflammation by modulating TLR signalling.</gtr:title><gtr:parentPublicationTitle>Mediators of inflammation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/98c1aca47b26397996ca3e73e352d69f"><gtr:id>98c1aca47b26397996ca3e73e352d69f</gtr:id><gtr:otherNames>Piccinini AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0962-9351</gtr:issn><gtr:outcomeId>D4GMac3jdb5</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>89007F35-093D-4AFE-A710-701C1E215D07</gtr:id><gtr:title>Targeting Toll-like receptors in autoimmunity.</gtr:title><gtr:parentPublicationTitle>Current drug targets</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7644082a26db28a6a7ae7d2ad5ed88a2"><gtr:id>7644082a26db28a6a7ae7d2ad5ed88a2</gtr:id><gtr:otherNames>Midwood KS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1389-4501</gtr:issn><gtr:outcomeId>585d636cad5ca3.65544524</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>861693C8-0501-476A-B839-3CF51900D8E1</gtr:id><gtr:title>Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells.</gtr:title><gtr:parentPublicationTitle>Journal of cellular physiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36f012c32fecef7697db71b289be6a08"><gtr:id>36f012c32fecef7697db71b289be6a08</gtr:id><gtr:otherNames>Verjee LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0021-9541</gtr:issn><gtr:outcomeId>pm_14219_29_20432463</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3C1A002-6B01-44E2-807E-D98583F305BC</gtr:id><gtr:title>Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/905e16968f95c6747894aa49589fff43"><gtr:id>905e16968f95c6747894aa49589fff43</gtr:id><gtr:otherNames>Goh FG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>aoXcWBcHgmJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A1778BFA-09FC-48E1-A723-5CEE1642D7B3</gtr:id><gtr:title>Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture.</gtr:title><gtr:parentPublicationTitle>The Journal of hand surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36f012c32fecef7697db71b289be6a08"><gtr:id>36f012c32fecef7697db71b289be6a08</gtr:id><gtr:otherNames>Verjee LS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0363-5023</gtr:issn><gtr:outcomeId>56d053d49b7397.22700741</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9D6F6E69-F434-40ED-BB5F-CE757B16CB1F</gtr:id><gtr:title>Cryptic domains of tenascin-C differentially control fibronectin fibrillogenesis.</gtr:title><gtr:parentPublicationTitle>Matrix biology : journal of the International Society for Matrix Biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1753d21eb1715bba9efeb3b291ffc760"><gtr:id>1753d21eb1715bba9efeb3b291ffc760</gtr:id><gtr:otherNames>To WS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0945-053X</gtr:issn><gtr:outcomeId>pm_14219_29_20708078</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>368DDB17-BC08-4463-AFC0-FC88029290E6</gtr:id><gtr:title>Startups on the menu.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a35ea88de80190cc989c086576123d2a"><gtr:id>a35ea88de80190cc989c086576123d2a</gtr:id><gtr:otherNames>Midwood K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>pm_14219_29_23752426</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0700108</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>149FA87E-B8CD-4FFC-B515-EAD312BED03B</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Musculoskeletal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>